fingolimod hydrochloride has been researched along with mitoxantrone in 20 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (mitoxantrone) | Trials (mitoxantrone) | Recent Studies (post-2010) (mitoxantrone) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 4,555 | 1,042 | 1,004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chun, J; Hale, J; Lariosa-Willingham, K; Lin, FF; Mandala, S; Rao, TS; Tham, CS; Webb, M; Yu, N | 1 |
| Gonsette, RE | 1 |
| Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S | 1 |
| Martin, R | 1 |
| Carmona, O; Cocco, E; Drulovic, J; Duddy, M; Eggers, C; Gold, R; Haghikia, A; Zéphir, H | 1 |
| Arnason, B | 1 |
| Sørensen, PS | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 1 |
| Graves, D; Vernino, S | 1 |
| McDonald, EA; Sedal, L; Wilson, IB | 1 |
| Gündel, M; Hofmann-Apitius, M; Kotelnikova, E; Lozano-Rubi, R; Malhotra, A; Martinez-Lapiscina, EH; Martinez-Lapsicina, EH; Mevissen, HT; Mueller, B; Pastor, X; Rajput, AM; Saiz, A; Toldo, L; Villoslada, P; Zubizarreta, I | 1 |
| Cocco, E; Coghe, GC; Fenu, G; Frau, F; Lorefice, L; Marrosu, MG | 1 |
| Berkowitz, AL; Kaplan, TB; Samuels, MA | 1 |
| Weinshenker, BG; Wingerchuk, DM | 1 |
| Airody, A; Gale, RP; Heath, G | 1 |
| Fernández, Ó | 1 |
| Chataway, J; Doshi, A | 1 |
| Axelsson, M; Dubuisson, N; Giovannoni, G; Gnanapavan, S; Lycke, J; Malmeström, C; Novakova, L | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Callegari, I; Derfuss, T; Galli, E | 1 |
13 review(s) available for fingolimod hydrochloride and mitoxantrone
| Article | Year |
|---|---|
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Topics: Antibodies, Monoclonal; Cladribine; Cyclophosphamide; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoxazoles; Ligands; Mitoxantrone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Azathioprine in multiple sclerosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Chemistry, Pharmaceutical; Cyclophosphamide; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Methotrexate; Methyltransferases; Mitoxantrone; Models, Chemical; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2008 |
Managing MS in a changing treatment landscape.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2011 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Immunosuppressive Agents; Infusions, Intravenous; Interferon-beta; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Plasmapheresis; Propylene Glycols; Pulse Therapy, Drug; Sphingosine; Spinal Cord | 2012 |
Immunotherapies in neurologic disorders.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Cyclosporine; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Mycophenolic Acid; Natalizumab; Nervous System Diseases; Peptides; Plasma Exchange; Propylene Glycols; Rituximab; Sphingosine; Tacrolimus | 2012 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines | 2014 |
Induction and escalation therapies in multiple sclerosis.
Topics: Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Induction Chemotherapy; Interferon-beta; Maintenance Chemotherapy; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Randomized Controlled Trials as Topic; Toluidines; Treatment Outcome | 2015 |
Cardiovascular Dysfunction in Multiple Sclerosis.
Topics: Animals; Autonomic Nervous System; Blood Pressure; Cardiovascular Abnormalities; Fingolimod Hydrochloride; Heart Rate; Humans; Mitoxantrone; Multiple Sclerosis | 2015 |
Disease modifying therapies for relapsing multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Injections; Interferon-beta; Magnetic Resonance Imaging; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Toluidines | 2016 |
The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Eye Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferons; Mitoxantrone; Multiple Sclerosis; Natalizumab | 2017 |
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Topics: Alemtuzumab; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Precision Medicine; Risk Assessment; Risk Factors; Treatment Outcome | 2017 |
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2017 |
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Indans; Interferon-beta; Male; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Oxadiazoles; Pregnancy; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Toluidines | 2021 |
7 other study(ies) available for fingolimod hydrochloride and mitoxantrone
| Article | Year |
|---|---|
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Immunosuppressive Agents; Interferon-gamma; Lymphocytes; Lymphopenia; Mice; Mice, Inbred Strains; Mitoxantrone; Molecular Sequence Data; Myelin Proteins; Myelin Proteolipid Protein; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peptide Fragments; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; Time Factors | 2004 |
Multiple sclerosis: closing in on an oral treatment.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2010 |
MS Forum/MS Over the Past 17 Years.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Recurrence | 2011 |
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Pharmacovigilance; Propylene Glycols; Risk Assessment; Sphingosine | 2011 |
Knowledge retrieval from PubMed abstracts and electronic medical records with the Multiple Sclerosis Ontology.
Topics: Antineoplastic Agents; Antirheumatic Agents; Biological Ontologies; Computational Biology; Electronic Health Records; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Information Storage and Retrieval; Knowledge Discovery; Mitoxantrone; Multiple Sclerosis; PubMed; Rituximab | 2015 |
Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
Topics: Adult; Biomarkers; CD56 Antigen; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2019 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |